Global Haematology and Flow Cytometry Market

The Haematology and Flow Cytometry Market size was valued at USD 5.81 Billion in 2025 and the total Haematology and Flow Cytometry revenue is expected to grow at a CAGR of 8.1% from 2025 to 2032, reaching nearly USD 10.03 Billion by 2032.

Haematology and Flow Cytometry Market Overview:

Hematology is a medical specialty that deals with the study and treatment of blood. This is concerned with the diagnosis, study, treatment, and prevention of blood diseases. Flow cytometry is an analytical tool that is used in the measurement and analysis of several physical characteristics of cells or particles suspended in a fluid using a laser beam. The method helps to subclassify cell types to decide on the best treatment plan.
To know about the Research Methodology :- Request Free Sample Report

Haematology and Flow Cytometry Market Dynamics:

Rising global incidence and prevalence of chronic diseases like blood cancer is the major driving factor for the market growth.

According to the National Cancer Institute in 2021, it was being estimated that 60,300 new leukemia cases are diagnosed and the deaths are around 24,470 cases in the United States. The increasing number of HIV cases globally is an important driver for the flow cytometry market. This is because the flow cytometry technique has its direct application in HIV diagnosis. According To UNAIDS in 2021, 31.1-43.9 million people globally are living with HIV by out of which 1.8 million are newly affected with HIV. Flow cytometry uses light scattering to determine the identity of cells. Increasing adoption of flow cytometry techniques in research and academia and growing initiatives in the field of immunology and Immuno-oncology researches are expected to propel the growth of the global flow cytometry market. Growth in stem cell research and the development of high-throughput flow cytometry technologies are likely to add new opportunities for this market in the coming years. Increasing regulatory approval and the introduction of technologically advanced flow cytometry solutions are expected to facilitate market growth over the forecast period. For instance, in June 2021, Sysmex Corporation launched the XF-1600 flow cytometer for laboratories, in North America.

A significant restraint on the flow cytometry market is the availability of cheaper and better alternatives. ELISA (enzyme-linked immunosorbent assay) and radioimmunoassay are two of these alternatives. Although flow cytometry, ELISA, and radioimmunoassay are all methods for detecting "problem cells" in a community of cells, ELISA and radioimmunoassay are less expensive and easier to use. Along with this, the dearth of skilled technicians for managing such advanced technology is expected to restrain the market growth.

The report has profiled twenty key players in the market from different regions. However, report has considered all market leaders, followers and new entrants with investors while analyzing the market and estimation the size of the same. Increasing R&D activities in each region are different and focus is given on the regional impact on the cost, availability of advanced technology are analyzed and report has come up with recommendations for future hot spot in APAC region.

Haematology and Flow Cytometry Market Segment Analysis:

The Global Haematology and Flow Cytometry Market is segment on the basis of Product, Technology and End-Users.

Based on Product, the flow cytometry instruments segment is expected to dominate the global market. The segment is further classified into cell analyzers and cell sorters. It held a market share of 25% in 2025. This high share is attributed to new advancements in technology and the introduction of novel cytometers by key players. The high price of these instruments is also contributing toward the high revenue generation in this segment.

Along with this, reagents and consumables also held a prominent share in 2025. Owing to their increased adoption in diagnostics and research the segment is expected to register lucrative growth over the forecast period. The large share of this segment is mainly attributed to the growing research activities to develop and prove the efficacy of various assays and kits, and the commercialization of high-quality and application-specific consumables, reagents, and assays.

Based on technology, the cell-based flow cytometry segment held the largest market share of 76% in 2025. The highest share is due to an increase in demand for early diagnosis and increased understanding of the related benefits of cell-based assays. In addition, advances in cell-based assay technology, such as innovations in tools, labels, affinity reagents, software, and algorithms, are expected to accelerate adoption in the coming years.

Haematology and Flow Cytometry Market Regional Insights:

North America dominated the global market in 2025.

The region dominated the global market in 2025 by holding a market share of 39.1%. This dominance is attributed due to the United States' high healthcare spending, well-developed healthcare system, and widespread adoption of technologically advanced flow cytometry solutions. In addition, the established pharmaceutical industry, as well as extensive research activities by research universities and pharmaceutical companies has generated huge demand for flow cytometry solutions for research universities and pharmaceutical companies have created a huge demand for flow cytometry solutions for research needs.

APAC region is projected to exhibit highest CAGR during forecast period.This high growth can be attributed to the extensive growth in the pharmaceutical and biotechnology industries of emerging economies, such as China and India. The lucrative growth exhibited by this region is also an outcome of continuous government support for the establishment of the pharmaceutical industry in emerging countries.

The report also helps in understanding Global Haematology and Flow Cytometrys Market dynamics, structure by analyzing the market segments and project the Global Haematology and Flow Cytometrys Market size. Clear representation of competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence in the Global Haematology and Flow Cytometrys Market make the report investor’s guide.

Haematology and Flow Cytometry Market, key developments:

• In September 2018, the U.S. FDA awarded a grant of ~$18 million over a period of four years for 12 new clinical trials. These clinical trials are aimed at developing products for patients with rare diseases (including primary sclerosing cholangitis, stargardt disease, Cushing disease, acute myeloid leukemia, and graft versus host disease, among others).

• In March 2017, Cytek Biosciences Inc., a manufacturer and supplier of flow cytometry products and services launched its DxP Athena flow cytometry system. The system is compact, powerful, easy-to-use cell analyzer that are typically only found in conventional instruments that come with a much higher price tag. The DxP Athena makes the benefits of flow cytometry which are more readily available to larger number of researchers by its compact size.

• In 2016, the Global Clinical Trials Fund (U.K.) launched a dedicated fund with an upper limit of $662,185 to support clinical trials across the world related to the testing of new experimental drugs and existing drugs developed for dementia.

Haematology and Flow Cytometry Market Scope: Inquire before buying

Haematology and Flow Cytometry Market, by Region

North America (United States, Canada, and Mexico)
Europe (UK, France, Germany, Italy, Spain, Sweden, Austria, and the Rest of Europe)
Asia Pacific (China, South Korea, Japan, India, Australia, ASEAN, Indonesia, Philippines, Malaysia, Vietnam, Thailand, ASEAN, Rest of Asia Pacific)
Middle East & Africa (South Africa, GCC, Nigeria, Rest of ME&A)
South America (Brazil, Argentina, Rest of South America)

Haematology and Flow Cytometry Market, Key players:

1. Becton, Dickinson and Company
2. Beckman Coulter, Inc.
3. Bio-Rad Laboratories, Inc.
4. Thermo Fisher Scientific, Inc.
5. Merck KGaA
6. Sysmex Partec GmbH
7. Luminex Corporation
8. Miltenyi Biotec GmbH
9. Sony Biotechnology
10. Abbott
11. Agilent Technologies
12. CellaVision
13. Horiba
14. Nihon Kohden
15. Ortho-Clinical Diagnostics
16. Roche
17. Siemens Healthineers
18. Sysmex
19. Miltenyi Biotec
20. Apogee Flow Systems Ltd.

Frequently Asked Questions:

1. Which region has the largest share in Global Haematology and Flow Cytometry Market?
Ans: North America region held the highest share in 2025.

2. What is the growth rate of Global Haematology and Flow Cytometry Market?
Ans: The Global Haematology and Flow Cytometry Market is growing at a CAGR of 8.1% during forecasting period 2026-2032.

3. What is scope of the Global Haematology and Flow Cytometry Market report?
Ans: Global Haematology and Flow Cytometry Market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period.

4. Who are the key players in Global Haematology and Flow Cytometry Market?
Ans: The important key players in the Global Haematology and Flow Cytometry Market are – Becton, Dickinson and Company, Beckman Coulter, Inc., Bio-Rad Laboratories, Inc., Thermo Fisher Scientific, Inc., Merck KGaA, Sysmex Partec GmbH, Luminex Corporation, Miltenyi Biotec GmbH, Sony Biotechnology, Abbott, Agilent Technologies, CellaVision, Horiba, Nihon Kohden, Ortho-Clinical Diagnostics, Roche, Siemens Healthineers, Sysmex, Miltenyi Biotec, and Apogee Flow Systems Ltd..

5. What is the study period of this Market?
Ans: The Global Haematology and Flow Cytometry Market is studied from 2025 to 2032.